Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents

Pediatric Infectious Disease Journal

Volumn 31, Issue 3, 2012, Pages 273-277

  Briz, Verónica ^a   León Leal, Juan A ^b   Palladino, Claudia ^a   Moreno Perez, David ^c   De Ory, Santiago J ^b   De José, Ma Isabel ^d   González Tomé, Ma Isabel ^e   Martín, César Gavilán ^f   Pocheville, Itziar ^g   Ramos, José T ^h   Leal, Manuel ^b   Muñoz Fernández, Ma Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

^h HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

HAART; mother to child HIV infected children and adolescents; raltegravir

Indexed keywords

DARUNAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; LOPINAVIR; MARAVIROC; RALTEGRAVIR; RITONAVIR; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMORBIDITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HERPETIC STOMATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; THRUSH; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRROLIDINONES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84857639900     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824580e8     Document Type: Article

References (12)

1. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000; 287:646-650. (Pubitemid 30070911)
2. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010;50:605-612.
3. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
4. Wiznia A, Samson P, Acosta E, et al. Safety and efficacy of raltegravir in pediatric HIV infection. Preliminary analysis from the International Maternal Pediatric Adolescent AIDS Clinical Trials Group, P1066. In: 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009); February 8-11, 2009; Montreal, Canada. Abstract 874.
5. Nachman S, Acosta E, Samson P, et al. Pharmacokinetic (PK), safety and efficacy data on cohort IIA; youth aged 6-11 from IMPAACT P1066: a phase I/II study to evaluate raltegravir (RAL) in HIV-1 infected youth. In: 17th Conference on Retroviruses and Opportunistic Infections (CROI 2009); February 16-19, 2010; San Francisco, CA. Abstract 873.
6. Nachman S, Acosta E, Zheng N, et al. Interim results from IMPAACT P1066: raltegravir (RAL) oral chewable tablet (CT) formulation in children 2-5 years. In: 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011); February 27-March 2, 2011; Boston, MA. Abstract S-108.
7. Pharmacokinetic effects of new antiretroviral drugs on children, adolescents and young adults. Available at: http://clinicaltrials.gov/ct2/show/ NCT00977756. Accessed May 26, 2010.
8. Garcia-Merino I, de Las Cuevas N, Jiménez JL, et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology. 2009;6:27.
9. Gupta RK, Gibb DM, Pillay D. Management of paediatric HIV-1 resistance. Curr Opin Infect Dis. 2009;22:256-263.
10. Eron J, Cooper D, Steigbigel T, et al. Sustained antiretroviral effect of raltegravir at week 156 in the BENCHMRK studies and exploratory analysis of late outcomes based on early virologic responses. In: 17th Conference on Retroviruses and Opportunistic Infections 2010; Feb 16-19, 2010. San Francisco, CA. Abstract 515.
11. Thuret I, Chaix ML, Tamalet C, et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS. 2009;23: 2364-2366.
12. Wittkop L, Breilh D, Da Silva D, et al. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy. J Antimicrob Chemother. 2009;63:1251-1255.